Navigation Links
Bavituximab in Medical News

Peregrine Pharmaceuticals Completes Planned Patient Enrollment in Bavituximab Phase I Cancer Trial

- Completion of Phase I Paves Way for Expanding Bavituximab Cancer Program - - Inclusion of Patients with Diverse Advanced Cancers Along with Promising Interim Phase II Data Suggest Bavituximab Could Have Broad Anti-Cancer Utility - TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Pereg...

ASCO Research Foundation Grant Will Support Study of Peregrine's Bavituximab in Lung Cancer

- Career Development Award to Study Biology of Bavituximab and Chemotherapy in Lung Cancer Awarded to Dr. David Gerber of UT Southwestern Medical Center - - New Study Complements Ongoing Bavituximab Plus Carboplatin/Paclitaxel Phase II NSCLC Trial that has Shown Promising Preliminary Results ...

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study

--Preliminary Data from Ongoing Study Shows Seven of 14 Evaluable Patients Achieved Objective Tumor Response by the End of Two Treatment Cycles-- --Bavituximab Has Now Produced Positive Early Results in All Three Ongoing Phase II Combination Therapy Cancer Trials-- TUSTIN, Calif., Feb. 1...

Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals' Bavituximab to Cure Lethal Virus Infections

--PS-Targeting AntibodiesMay Represent a Completely New Class of Drugs with Broad Potential to Treat Life-Threatening Viral Infections-- --Peregrine's Clinical-Stage Anti-PS Agent Bavituximab and Equivalent Antibodies Cured Lethal Viral Infections in Preclinical Models-- --Data C...

Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer

- Republic of Georgia Drug Agency Approves Protocol for New Clinical Trial of Bavituximab in Combination with Docetaxel - TUSTIN, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical company developing monoclo...

Positive Results From Peregrine Pharmaceuticals' Bavituximab Phase l HCV Trial Presented at AASLD Meeting

- Bavituximab Appeared Generally Safe and Well Tolerated at All Doses Tested - - Signs of Anti-viral Activity Seen at All Dose Levels - - Exploratory Analysis of Cytokine Profile Following Treatment Supports Proposed Immunomodulatory Mechanism ...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

...Defense Threat Reduction Agency (DTRA) to evaluate bavituximab as a potential broad spectrum treatment for viral ...al and other development activities related to the bavituximab clinical program significantly increased. The com...commitment to significantly expand and advance our bavituximab Phase II clinical program, which is already yieldi...

New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report

...Ib Results of Debio 025 II-59 Nabi Biopharmaceuticals Starts Proof-Of-Concept Trial for Civacir II-60 Peregrine Announces Positive Results for bavituximab II-60 Jenken to Commence Phase II Trial of JBK-122 II-60 Pevion Biotech Initiates Phase I Study of Hepatitis C Vaccine II-61 Intercell Rel...

Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform

...with cancer. "PS-targeting antibodies such as bavituximab preferentially bind to tumor blood vessels, which ... Peregrine. "This patent protects expanded use of bavituximab and other PS-targeting antibodies to track disease...e target for cancer diagnostics and therapeutics. bavituximab is a monoclonal antibody that specifically targets...

Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program

... infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus (HCV) infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ( www.avidbio.com ),...
Bavituximab in Medical Technology

Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer - - 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer - - 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cance...

Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients

-Preliminary Data from This Trial to be Presented at ASCO- -First Phase II Trial in Bavituximab Cancer Program to Complete Patient Enrollment- TUSTIN, Calif., May 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it has completed enrollment...

Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial

- Updated Data from Initial Cohort Shows 11 of 17 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Initiated in Expansion Stage of Trial with Target of Enrolling 49 Patients Overall - TUSTIN, Cal...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial

- Planned 15 Patient Cohort Enrolled in Stage A of Trial Assessing Regimen of Bavituximab in Combination With Carboplatin and Paclitaxel - TUSTIN, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical company developing ...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

- Peregrine Achieves Milestone as Third Phase II Trial in Its Bavituximab Cancer Program Begins Patient Enrollment and Dosing - TUSTIN, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that patient screening and dosing has begun ...

Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer

- Pre-Specified Primary Efficacy Endpoint Met in Stage 1 of Two-Stage Study - - 100% of Evaluable Patients to Date Continue to Show Objective Tumor Response or Stable Disease - TUSTIN, Calif., July 2 /PRNewswire-FirstCall/ -- Peregrine Ph...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer

-- Peregrine's Second Phase II Bavituximab Cancer Trial Is Evaluating the Anti-Tumor Activity of Bavituximab in Combination with Carboplatin and Paclitaxel -- TUSTIN, Calif., June 30 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today ...

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial

- First 15 Patients Are Enrolled and Dosing With Bavituximab Plus Docetaxel Combination Regimen is Underway - TUSTIN, Calif., April 29 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical company developing monoclonal an...

Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer

-No Metastatic Lesions Were Detectable After Combination Therapy Treatment- -Survival Time More Than Doubled in Animals Treated with Combination Therapy- -Established Tumors Regressed by 50% After Combination Therapy Treatment- SAN DIEGO and TUSTIN, Calif., April...

Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents

- Researcher Participating in Bavituximab U.S. Cancer Trial Presents Data on Novel Anti-PS Monoclonal Antibody to Anti-Angiogenesis Experts - TUSTIN, Calif., Feb. 8 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical company developing...
Bavituximab in Biological News

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

TUSTIN, Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug ba...

Peregrine's PS-targeting antibodies highlighted in AACR Annual Meeting studies

...ti-PS pipeline. Peregrine's lead anti-PS antibody bavituximab is currently in Phase II clinical trials in advanc... About Peregrine's Clinical Stage Anti-PS Antibody bavituximab Peregrine's clinical stage PS-targeting antibody bavituximab binds to the cellular membrane component phosphati...
Bavituximab in Biological Technology

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and ...

Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting

- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer - - Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types - TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceutical...

Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial

- Updated Data from Initial Cohort Shows Nine of 14 Evaluable Patients Receiving Bavituximab in Combination with Carboplatin + Paclitaxel Achieved an Objective Tumor Response - - Patient Dosing Underway in Expansion Stage of Trial with Target of Enrolling 46 Patients Overall - TUSTIN, Ca...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

TUSTIN, Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug ba...

Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study

-Preliminary Data Show Seven of 17 Evaluable Patients Achieved an Objective Tumor Response by End of Four Treatment Cycles- TUSTIN, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that its lead product candidate bavituximab achieved th...

Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections

TUSTIN, Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug ba...

Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer

-Data Update Shows 71% of Evaluable Patients in the Trial's First Stage Achieved Objective Tumor Responses- -Patient Enrollment is Open in the Trial's Second Stage- TUSTIN, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cli...

Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial

- Planned Cohort of 21 Patients with Non-Small Cell Lung Cancer Enrolled in First Stage of Trial Assessing Regimen of Bavituximab with Carboplatin and Paclitaxel - TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a ...

Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers

- Five-Year Defense Threat Reduction Agency Contract Will Support Development of Bavituximab and Fully Human Equivalent as Potential Broad-Spectrum Anti-Viral Agents - TUSTIN, Calif., July 1 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), a cl...

Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study

- 50% of All Evaluable Patients in Phase I Study Receiving Combination of Bavituximab Plus Chemotherapy Achieved Objective Tumor Response or Stable Disease - - 100% of Evaluable Patients to Date in Ongoing Phase II Breast Cancer Study Showing Objective Tumo...
Other Tags
(Date:7/11/2014)... MA (PRWEB) July 11, 2014 ... at least $50 billion in fuel costs ... immediately. The current GHG standards ... have taken it upon themselves to install ... include: , 1.    Idle reduction technologies , 2.    Efficient ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down ... the Concord Pavilion . When it comes to the summer ... Bryan. The 37-year-old Georgia native is one of the biggest names ... entertainment business. Bryan is currently out on his “That’s My Kind ... many stops the tour will be making through the rest of ...
(Date:7/11/2014)... Global enterprises today are shifting towards ... management activities. Managed services offer these global enterprises a ... slowdown resulted into rising operational costs to companies. The ... to be the global market driver for expanding the ... managed services market is estimated to grow from $142.75 ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... (HealthDay News) -- Delaying surgery to repair damage to the ... middle of the knee -- could increase a young athlete,s ... medical records of 130 patients, aged 8 to 16, who ... less than six weeks after their injury, 37 had surgery ... more than three months after their injury. The youngsters ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
Other Contents